Table 1. Summary of the effects of SSAO inhibitors in mouse arthritis models of distinct mechanisms.

	CFA model		K/BxN model
	SzV-1287	LJP-1207	SzV-1287	LJP-1207
Mechanical hyperalgesia	↓	↓	↓	↓
Joint swelling	↓	↓	↓	↓
Semiquantitative score	n.a.	n.a.	↓	↓
Joint function	n.a.	n.a.	Ø	Ø
Neutrophil MPO-activity	Ø	Ø	Ø	↓
Plasma extravasation	Ø	Ø	↓	↓
Histopathological changes	↓	Ø	n.a.	n.a.

Both SzV-1287 and LJP-1207 significantly reduced CFA- and K/BxN serum-evoked mechanical hyperalgesia and joint swelling, as well as K/BxN serum-induced macroscopic clinical sings and plasma extravasation. K/BxN serum-evoked neutrophil MPO-activity was attenuated only by LJP-1207, CFA-induced histopathological destruction by SzV-1287. K/BxN serum-induced joint function impairment, CFA-evoked neutrophil MPO-activity and plasma extravasation were not affected by either treatment (↓: significantly reduced; Ø: not affected; n.a.: not analysed).